Quarterly report pursuant to Section 13 or 15(d)

7. INTANGIBLE ASSETS

v3.8.0.1
7. INTANGIBLE ASSETS
 3 Months Ended
Mar. 31, 2018
Intangible Assets  
7. INTANGIBLE ASSETS

Intangible assets at March 31, 2018 and December 31, 2017 consist of the following:

 

    March 31, 2018   December 31, 2017
        Accumulated           Accumulated    
    Cost   Amortization   Net   Cost   Amortization   Net
Trademark and other intangible rights related to Nabi-HB   $ 4,100,046     $ 488,101     $ 3,611,945     $ 4,100,046     $ 341,670     $ 3,758,376  
Rights to intermediates     907,421       108,026       799,395       907,421       75,618       831,803  
Customer contract     1,076,557       849,782       226,775       1,076,557       817,386       259,171  
    $ 6,084,024     $ 1,445,909     $ 4,638,115     $ 6,084,024     $ 1,234,674       4,849,350  

 

All of the Company’s intangible assets were acquired in the Biotest Transaction. Amortization expense related to these intangible assets for the three months ended March 31, 2018 was $0.2 million. Estimated aggregate future aggregate amortization expense for the next five years is expected to be as follows:

 

Remainder of 2018     $ 633,704  
2019       715,352  
2020       715,352  
2021       715,352  
2022       715,352